{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:22:04Z","timestamp":1772781724858,"version":"3.50.1"},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1993,7]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> This trial evaluated the activity and toxicity of a prolonged schedule of low-dose, daily infusional etoposide in patients with etoposide-sensitive neoplasms. <\/jats:p><\/jats:sec><jats:sec><jats:title>PATIENTS AND METHODS<\/jats:title><jats:p> Fifteen patients (non-Hodgkin's lymphoma, n = 10; small-cell lung cancer, n = 3; germ cell neoplasm, n = 2) were treated. Ten had received etoposide previously. Etoposide 18 to 25 mg\/m2\/d was administered by continuous intravenous infusion for at least 21 days, or until either leukocyte count decreased to less than 2,000\/microL, platelets decreased to less than 75,000\/microL, or tumor progressed. Plasma etoposide levels were monitored during infusion. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> Duration of therapy ranged from 21 to 560 days; uninterrupted infusion ranged from 21 to 153 days. Seven patients (47%) had an objective tumor response (six partial, one complete), with a median duration of 7 months (range, 2 to 19). Myelosuppression limited the infusion; however, only four patients had grade 4 leukopenia, and most tolerated infusions with mild to moderate leukopenia. Nine patients required RBC transfusions. Only one patient developed severe thrombocytopenia. Alopecia was universal; however, other grade 3 or 4 nonhematologic toxicities were not encountered. The mean serum etoposide concentration was 0.7 +\/- 0.42 microgram\/mL. Only three patients had serum etoposide levels greater than 1 microgram\/mL. <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> Etoposide administered as a low-dose continuous infusion is active in etoposide-sensitive neoplasms. Myelosuppression is the major toxicity, but seems reduced when compared with other schedules. Tumor cytotoxicity was demonstrated with plasma levels ranging from 0.5 to 1.0 microgram\/mL. Chronic low doses of etoposide may be superior to the standard dose and schedule and further study of this issue is warranted. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.1993.11.7.1322","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T14:05:47Z","timestamp":1487858747000},"page":"1322-1328","source":"Crossref","is-referenced-by-count":46,"title":["Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I\/II study."],"prefix":"10.1200","volume":"11","author":[{"given":"D S","family":"Thompson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J D","family":"Hainsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K R","family":"Hande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M C","family":"Holzmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F A","family":"Greco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1993.11.7.1322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T19:58:27Z","timestamp":1653508707000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1993.11.7.1322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,7]]},"references-count":0,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1993,7]]}},"alternative-id":["10.1200\/JCO.1993.11.7.1322"],"URL":"https:\/\/doi.org\/10.1200\/jco.1993.11.7.1322","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,7]]}}}